Colitis Ulcerative

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-08-26
EMA Authorised: Skyrizi (risankizumab) — AbbVie Deutschland GmbH & Co. KG
Regulatory authorization for Skyrizi (risankizumab) by AbbVie Deutschland GmbH & Co. KG across multiple inflammatory diseases.